Publicaciones en colaboración con investigadores/as de Universidade de Santiago de Compostela (25)

2019

  1. Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy

    EBioMedicine, Vol. 45, pp. 588-605

2017

  1. * Human Amniotic Mesenchymal Stromal Cells as Favorable Source for Cartilage Repair

    Tissue engineering. Part A, Vol. 23, Núm. 17-18, pp. 901-912

2016

  1. Differentiation of human mesenchymal stromal cells cultured on collagen sponges for cartilage repair

    Histology and Histopathology, Vol. 31, Núm. 11, pp. 1221-1239

  2. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. Alternative protocols to induce chondrogenic differentiation: transforming growth factor-β superfamily

    Cell and Tissue Banking, Vol. 16, Núm. 2, pp. 195-207

  2. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine

    Scientific Reports, Vol. 4

  2. Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus

    Arthritis Research and Therapy, Vol. 16, Núm. 3

  3. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  4. Proteomic applications in the study of human mesenchymal stem cells

    Proteomes, Vol. 2, Núm. 1, pp. 53-71

2013

  1. Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential

    Stem Cells International

  2. Lamin A deregulation in human mesenchymal stem cells promotes an impairment in their chondrogenic potential and imbalance in their response to oxidative stress

    Stem Cell Research, Vol. 11, Núm. 3, pp. 1137-1148

  3. Mitochondrial genetics and osteoarthritis

    Frontiers in Bioscience - Scholar, Vol. 5 S, Núm. 1, pp. 360-368

  4. New targets for disease modifying osteoarthritis drugs: Chondrogenesis and Runx1

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 5, pp. 631-634

2012

  1. Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: A case-control study

    Arthritis Research and Therapy, Vol. 14, Núm. 2

  2. Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study

    PLoS ONE, Vol. 7, Núm. 9

  3. Mitochondrial haplogroups define two phenotypes of osteoarthritis

    Frontiers in Physiology, Vol. 3 MAY

2011

  1. Association of systemic lupus erythematosus clinical features with european population genetic substructure

    PLoS ONE, Vol. 6, Núm. 12

  2. Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: A study in Spanish and Italian populations and meta-analysis

    Arthritis and Rheumatism, Vol. 63, Núm. 7, pp. 1860-1865

  3. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 5, pp. 864-867